“We’re pleased to align with the leader in this space to gain a broader lens into cybersecurity innovations and how they may impact our industry.” “TELUS is at the forefront of network security practices with an eye on the future of quantum safe technologies,” said Mario Mele, vice president Corporate Strategy, TELUS Ventures. We’re excited to support the QuintessenceLabs team as they scale their business and provide customers with a critical layer of protection.” “Dr Sharma and the team at QuintessenceLabs are global leaders in developing quantum-based cybersecurity tools that help protect sovereign and commercially sensitive information. “As computing power increases exponentially, the tools needed to secure critical data and assets must stay several steps ahead,” said Bill Bartee, Partner at Main Sequence. The company has been widely recognized for its cybersecurity innovations around the world, most recently through its selection as a World Economic Forum Global Innovator as well as winning a prestigious 2020 CyberTech100 Award. ”Īustralian-based QuintessenceLabs is a global leader in quantum cybersecurity recognized for its advanced quantum-safe data protection capabilities. “Safeguarding data-our most valuable resource-has never been more critical and we look forward to this exciting new growth stage while continuing to develop world-leading solutions to secure our increasingly digital lives. “We are delighted to have secured investments from Main Sequence and TELUS Ventures and be recognized for our breakthrough commercialization of quantum enhanced cybersecurity solutions,” said QuintessenceLabs’ Founder and CEO, Dr Vikram Sharma. The next issue of Financial Post Top Stories will soon be in your inbox. If you don't see it, please check your junk folder. v2food secures AU$77M in Series B funding to take Australian plant-based meat to the world, 20 October 2020.Co-create a company: If you see an opportunity in the market to bring your business or your research together to form a disruptive new company, contact Main Sequence to talk about bringing the right people together here.Invest in science-driven solutions: If you’re an investor, read more on the Main Sequence website about how to invest with Main Sequence here.Pitch your start-up or spin out: If your start-up or small business has origins or connections to the publicly-funded Australian research sector, pitch to Main Sequence here.You can read more about Main Sequence’s portfolio of investments and the global challenges they’re solving here. Main Sequence’s origins within CSIRO reflect its commitment to amplifying connections between industry, research and infrastructure to accelerate deep technology development, and reinvesting economic returns from commercialisation back into science.Ĭompanies created with CSIRO include Coviu telehealth platform, Emesent drone technology, RapidAim biosecurity solution, v2food alternative protein, and Nourish Ingredients. These companies have created over 1,200 jobs by working with partners in industry, CSIRO, and 22 Australian universities. The CSIRO Innovation Fund, managed by Main Sequence, has invested in 39 companies since it was formed in 2017. It solves the world’s greatest challenges by turning our scientific breakthroughs into the next century’s giants. Main Sequence was created by CSIRO to address the ‘valley of death’ between research and commercialisation.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |